Gabapentin
Product Images NDC 0440-5562

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0440-5562). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Liberty Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin-structure (Gabapentin Capsule 1)

Chemical structure of gabapentin showing its molecular framework with a cyclohexane ring attached to amine and carboxyl functional groups.*

FDA Label Image

Gabapentin-fig01 (Gabapentin Capsule 2)

A line graph comparing weekly mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin shows a decreasing pain trend significantly lower than placebo during the study.*

FDA Label Image

Gabapentin-fig02 (Gabapentin Capsule 3)

A line graph titled 'Figure 2. Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The x-axis represents weeks from baseline to 7, with annotations for a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis shows mean pain scores ranging from 0 to 10. Three lines depict placebo, gabapentin 1800 mg/day, and gabapentin 2400 mg/day, with both gabapentin doses showing lower mean pain scores compared to placebo throughout the period. Statistically significant differences (p < 0.01) are indicated along the gabapentin lines.*

FDA Label Image

Gabapentin-fig03 (Gabapentin Capsule 4)

A bar chart comparing the percentage of responders at endpoint in two controlled PHN studies. Study 1 shows 12% for placebo (PBO) and 29% for gabapentin (GBP) 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg. Statistical significance is indicated for the GBP groups compared to placebo.*

FDA Label Image

Gabapentin-fig04 (Gabapentin Capsule 5)

A scatter plot illustrating the responder rate difference (%) from placebo by daily dose (mg) of Gabapentin in three studies (a, b, c). The x-axis represents daily dose ranging 600 to 1800 mg, and the y-axis represents difference in responder rate from 2% to 22%. Study a is marked by solid black squares, Study b by gray squares, and Study c by white squares. The plot shows dose-related differences in responder rates in adjunctive therapy for patients 12 years or older with partial seizures.*

FDA Label Image

Image (Gabapentin Capsule 6)

GABAPENTIN, USP 600 mg capsules bottle label with 30 capsules, labeled as generic for brand Neurontin, by Liberty Pharmaceuticals Inc. The label includes manufacturing details for Exelan Pharmaceuticals, Inc., and packaging by Aidarex Pharmaceuticals LLC. It features dosage strength, quantity, barcodes, and cautionary federal law dispensing warning.*

FDA Label Image

Image (Gabapentin Capsule 7)

Label for Gabapentin USP 800 mg capsules, 180 count, generic for Neurontin, labeled by Liberty Pharmaceuticals Inc. The label indicates prescription only use and includes packaging information by Aidarex Pharmaceuticals LLC, with manufacturing by Exelan Pharmaceuticals, Inc. Dosage form is capsules, described as white oblong with a score 3 on one side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.